IMNN

Imunon, Inc. (IMNN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA therapeutics. Its lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in a Phase 3 trial (OVATION 3). The company also maintains a vaccine platform, PlaCCine, with a COVID-19 booster candidate (IMNN-101) that has completed Phase 1 dosing. Imunon is classified as a smaller reporting company and a non-accelerated filer.

Key Financial Metrics

Note: The company has no debt obligations listed on the balance sheet other than operating lease liabilities.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $147,000 (3.6%) compared to Q1 2025, driven primarily by higher Research and Development (R&D) expenses.
• R&D Expenses: Increased by $172,000 (8.0%) to $2.34 million. This was due to a $380,000 increase in non-clinical R&D and CMC costs for the OVATION program, partially offset by a $159,000 decrease in manufacturing costs and a $55,000 decrease in PlaCCine vaccine trial costs.
• General and Administrative (G&A): Remained relatively flat, decreasing slightly by $11,000 to $1.97 million.
• Cash Burn: Net cash used in operating activities increased by $1.14 million to $4.0 million, reflecting higher operating outflows.
• Stock Activity: The company exercised pre-funded warrants for 503,114 shares during the quarter. No shares were sold under the At-The-Market (ATM) program during Q1 2026, though 146,354 shares were sold subsequent to the quarter end.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has determined there is substantial doubt about the company's ability to continue as a going concern. With $4.8 million in cash and a burn rate of approximately $4 million per quarter, current capital is not expected to fund operations for the next twelve months without additional financing.
• Financing Strategy: The company plans to raise capital through public or private equity sales, debt facilities, strategic partnerships, or out-licensing. It maintains an ATM program with $12.2 million in registered capacity (as of March 2026).
• Clinical Progress:
  • OVATION 3 (Phase 3): Enrollment is on track to complete by the first half of 2029. Seven sites are currently open.
  • OVATION 2 (Phase 2): Final data announced March 25, 2026, showed a median 14.7-month increase in overall survival compared to standard of care.
  • IMNN-101 (Vaccine): Further development has been paused pending partnership opportunities.
• Risks: Key risks include the inability to raise additional capital, volatility in financial markets, regulatory approval uncertainties, and the inherent risks of drug development.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $4.8 million cash balance against the ~$4 million quarterly burn rate and the timeline for the next financing event.
• ATM Program Status: Confirm the current utilization of the $12.2 million ATM capacity and recent share sales activity post-March 31, 2026.
• Phase 3 Enrollment: Monitor the progress of the OVATION 3 trial enrollment against the projected H1 2029 completion date.
• Dilution Impact: Assess the potential dilution from future equity raises, noting the existing 4.0 million warrants outstanding and the 15-for-1 reverse stock split history.
• Going Concern Mitigation: Review any subsequent filings for evidence of secured funding or strategic partnerships to address the substantial doubt expressed in the filing.